SCHEMBL2096503

SCHEMBL2096503

O=[C]Oc1ccccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.39
IDO1 P14902 2/20 0.37
GAA P10253 2/20 0.36
LMNA P02545 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
MAOB P27338 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
NOTUM Q6P988 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094129 0.84 RXRA (0.33) PPARGRXRARXRBRXRGMRGPRX4
SCHEMBL20718950 0.81 RXRA (0.39) PPARGRXRARXRBRXRGMRGPRX4
SCHEMBL8983336 0.79 TSHR (0.31) LMNA
SCHEMBL3636639 0.79 TDP1 (0.45) RXRARXRBRXRGGAALMNA
SCHEMBL17914533 0.79 AR (0.40) PPARGRXRARXRBRXRGIDO1
SCHEMBL6571065 0.77 CA1 (0.38) GAALMNAADRA2BALDH1A1TDP1
SCHEMBL2095724 0.75 RXRA (0.41) RXRARXRBRXRGGAASLC22A12
SCHEMBL1685381 0.75 LTA4H (0.46) PPARGRXRARXRBRXRGMRGPRX4
SCHEMBL5307469 0.75 RXRA (0.49) PPARGRXRARXRBRXRGMRGPRX4
SCHEMBL11048002 0.73 LTA4H (0.45) PPARGRXRARXRBRXRGMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006117743-A1 SUBSTITUTED AROMATIC COMPOUNDS AS ANTIDIABETIC AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO claimed
EP-1019378-A4 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS LILLY CO ELI (US) 2001-09-26 EP claimed
EP-0925063-A4 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS LILLY CO ELI (US) 2000-12-27 EP claimed
EP-1019378-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 2000-07-19 EP claimed
EP-0925063-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1999-06-30 EP claimed
WO-1998000137-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1998-01-08 WO claimed
WO-1998000403-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1998-01-08 WO claimed
US-11695158-B2 Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same MU IONIC SOLUTIONS CORPORATION (JP) 2023-07-04 US disclosed
US-20210320334-A1 NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME MU IONIC SOLUTIONS CORPORATION (JP) 2021-10-14 US disclosed
US-20190198928-A1 NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME UBE INDUSTRIES, LTD. (JP) 2019-06-27 US disclosed
EP-3086396-B1 NONAQUEOUS ELECTROLYTE WITH CARBOXYLIC ACID ESTER COMPOUND AND ENERGY STORAGE DEVICE USING SAME UBE INDUSTRIES (JP) 2019-06-05 EP disclosed
US-10263285-B2 Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same UBE INDUSTRIES, LTD. (JP) 2019-04-16 US disclosed
US-20180166746-A1 NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME UBE INDUSTRIES, LTD. (JP) 2018-06-14 US disclosed
EP-0925063-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1999-06-30 EP disclosed
WO-1998000137-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1998-01-08 WO disclosed
WO-1998000403-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1998-01-08 WO disclosed
EP-0543662-B1 Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO CO (JP) 1996-09-18 EP disclosed
US-5506362-A Process for the preparation of an α-amino acid amide SOLVAY (SOCIETE ANONYME) (BE) 1996-04-09 US disclosed
EP-0633267-A1 Process for the preparation of an alpha-amino acid amide for use in peptide synthesis SOLVAY (Société Anonyme) (BE) 1995-01-11 EP disclosed
EP-0543662-A2 Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1993-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180166746-A1 NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME SLC9A2, VDAC1, SCO2 PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885
US-20190198928-A1 NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME SLC9A2, VDAC1, SCO2 PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885
US-11695158-B2 Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same SLC9A2, VDAC1, SCO2 PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885
US-10263285-B2 Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same SLC9A2, VDAC1, SCO2 PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885
US-20210320334-A1 NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME SLC9A2, VDAC1, SCO2 PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.